---
title: "Highly effective new antiviral"
image: "https:\/\/i.ytimg.com\/vi\/EMfjtgli55Y\/hqdefault.jpg"
vid_id: "EMfjtgli55Y"
categories: "Education"
tags: ["physiology","nursing","NCLEX"]
date: "2021-11-08T12:51:59+03:00"
vid_date: "2021-11-07T20:57:11Z"
duration: "PT26M3S"
viewcount: "155251"
likeCount: "5692"
dislikeCount: "451"
channel: "Dr. John Campbell"
---
{% raw %}Protectors from hospitalization, the story so far<br /><br />Oral meds than can be prescribed from home with onset of symptoms<br /><br />Molnupiravir, approved by MHRA<br /><br /><a rel="nofollow" target="blank" href="https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra">https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra</a><br /><br />The antiviral was found to be safe and effective following a stringent review of the available evidence.<br /><br /><a rel="nofollow" target="blank" href="https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/">https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/</a><br /><br />Public domain data, Merck press release<br /><br />$ 700 per 5-day course<br /><br />Under 50% reduction in deuteriation<br /><br />Effect of early treatment with fluvoxamine<br /><br />Together Trial group<br /><br />Public domain data, Peer reviewed trial in the Lancet<br /><br /><a rel="nofollow" target="blank" href="https://clinicaltrials.gov/ct2/show/NCT04727424">https://clinicaltrials.gov/ct2/show/NCT04727424</a><br /><br /><a rel="nofollow" target="blank" href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext">https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext</a><br /><br />Adults with a risk factor<br /><br />$4 for a 10-day course<br /><br />32% protection against hospitalization<br /><br />32% protection against death<br /><br />Fluvoxamine is approved by the Food and Drug Administration as an antidepressant<br /><br />Doctors already can prescribe it off-label — using their clinical judgment<br /><br /><a rel="nofollow" target="blank" href="https://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/?">https://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/?</a><br /><br /><a rel="nofollow" target="blank" href="https://bnf.nice.org.uk/drug/fluvoxamine-maleate.html">https://bnf.nice.org.uk/drug/fluvoxamine-maleate.html</a><br /><br /><a rel="nofollow" target="blank" href="https://www.togethertrial.com">https://www.togethertrial.com</a><br /><br />Ivermectin, Together trial results not yet released<br /><br /><br />PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY<br /><br /><a rel="nofollow" target="blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate">https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</a><br /><br />Public domain data, Pfizer press release<br /><br />PAXLOVID™ (PF-07321332; ritonavir)<br /><br />Found to reduce the risk of hospitalization or death by 89% <br /><br />Compared to placebo in non-hospitalized high-risk adults with COVID-19<br /><br />Through Day 28<br /><br />PAXLOVID group<br /><br />No deaths<br /><br />Placebo group<br /><br />10 deaths<br /><br />Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible<br /><br />Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) <br /><br />Randomized, double-blind study of non-hospitalized adult patients with COVID-19, <br /><br />who are at high risk of progressing to severe illness <br /><br />Scheduled interim analysis<br /><br />89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo<br /><br />In patients treated within 3 days of symptom onset<br /><br />PAXLOVID group<br /><br />0.8% of patients hospitalized<br /><br />3/389 hospitalized with no deaths<br /><br />Placebo group<br /><br />7.0% of patients hospitalized or died<br /><br />27/385 hospitalized<br /><br />with 7 subsequent deaths<br /><br />(p less than 0.0001) 1 in 10,000 chance<br /><br />In patients treated within 5 days of symptom onset<br /><br />PAXLOVID group<br /><br />1.0% of patients hospitalized<br /><br />6/607 hospitalized with no deaths<br /><br />Placebo group<br /><br />6. 7% of patients hospitalized or died<br /><br />41/612 hospitalized,<br /><br />with 10 subsequent deaths<br /><br />p less than 0.0001<br /><br />At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer will cease further enrollment into the study<br /><br />due to the overwhelming efficacy demonstrated in these results<br /><br />About the Phase 2/3 EPIC-HR Study Interim Analysis<br /><br />1,219 adults enrolled out of 3,000 planned<br /><br />North and South America, Europe, Africa, and Asia<br /><br />Enrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infection<br /><br />Mild to moderate symptoms<br /><br />At least one characteristic or underlying medical condition<br /><br />Randomized (1:1) to receive PAXLOVID™ or placebo orally every 12 hours for five days<br /><br />About the Phase 2/3 EPIC-HR Study Safety Data<br /><br />Safety data, n = 1881<br /><br />Treatment-emergent adverse events<br /><br />PAXLOVID™group<br /><br /> 19%<br /><br />Placebo group<br /><br />21%<br /><br />Most of which were mild in intensity<br /><br />Fewer serious adverse events<br /><br />PAXLOVID™group<br /><br /> 1.7%<br /><br />Placebo group<br /><br />6.6%<br /><br />Discontinuation of study drug due to adverse events<br /><br />PAXLOVID™group<br /><br />2.1%<br /><br />Placebo group<br /><br />4.1%<br /><br />Pharmacology<br /><br />Specifically designed SARS-CoV-2-3CL protease inhibitor,<br /><br />an enzyme that the coronavirus needs to replicate<br /><br />Co-administration with a low dose of ritonavir helps slow the metabolism of PF-07321332<br /><br />PF-07321332 inhibits viral replication at a stage known as proteolysis, <br /><br />which occurs before viral RNA replication<br /><br />In preclinical studies, PF-07321332 did not demonstrate evidence of mutagenic DNA interactions.<br /><br />EPIC-SR includes a cohort of vaccinated patients who have an acute breakthrough symptomatic COVID-19 infection and who have risk factors for severe illness.{% endraw %}
